Frontiers in Oncology (Aug 2024)
Is precision medicine the solution to improve organ preservation in laryngeal/hypopharyngeal cancer? A position paper by the Preserve Research Group
- Davide Mattavelli,
- Davide Mattavelli,
- Gunnar Wichmann,
- Davide Smussi,
- Davide Smussi,
- Alberto Paderno,
- Maria Serrahima Plana,
- Ricard Nin Mesia,
- Micaela Compagnoni,
- Alessandro Medda,
- Susanna Chiocca,
- Stefano Calza,
- Yinxiu Zhan,
- Carla Rognoni,
- Rosanna Tarricone,
- Rosanna Tarricone,
- Erika Stucchi,
- Erika Stucchi,
- Luigi Lorini,
- Cristina Gurizzan,
- Ksenia Khelik,
- Eivind Hovig,
- Eivind Hovig,
- Andreas Dietz,
- Cesare Piazza,
- Cesare Piazza,
- Paolo Bossi,
- Paolo Bossi
Affiliations
- Davide Mattavelli
- Unit of Otorhinolaryngology – Head and Neck Surgery, ASST Spedali Civili di Brescia, Brescia, Italy
- Davide Mattavelli
- Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia, Brescia, Italy
- Gunnar Wichmann
- Clinic of Otolaryngology, Head and Neck Surgery, Department of Head Medicine and Oral Health, University Hospital Leipzig, Leipzig, Germany
- Davide Smussi
- Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia, Brescia, Italy
- Davide Smussi
- Unit of Medical Oncology, ASST Spedali Civili di Brescia, Brescia, Italy
- Alberto Paderno
- Department of Biomedical Sciences, Humanitas University (Milan), IRCCS Humanitas Research Hospital, Rozzano, Italy
- Maria Serrahima Plana
- Medical Oncology Department, Institut Català d’Oncologia (ICO-Hospitalet), IDIBELL, Hospitalet de Llobregat, Barcelona, Spain
- Ricard Nin Mesia
- Medical Oncology Department, Institut Català d’Oncologia (ICO-Hospitalet), IDIBELL, Hospitalet de Llobregat, Barcelona, Spain
- Micaela Compagnoni
- Department of Experimental Oncology, IEO, European Institute of Oncology IRCCS, Milan, Italy
- Alessandro Medda
- Department of Experimental Oncology, IEO, European Institute of Oncology IRCCS, Milan, Italy
- Susanna Chiocca
- Department of Experimental Oncology, IEO, European Institute of Oncology IRCCS, Milan, Italy
- Stefano Calza
- Unit of Biostatistics and Bioinformatics, Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy
- Yinxiu Zhan
- Department of Experimental Oncology, IEO, European Institute of Oncology IRCCS, Milan, Italy
- Carla Rognoni
- Centre for Research on Health and Social Care Management (CERGAS), SDA Bocconi School of Management, Bocconi University, Milan, Italy
- Rosanna Tarricone
- Centre for Research on Health and Social Care Management (CERGAS), SDA Bocconi School of Management, Bocconi University, Milan, Italy
- Rosanna Tarricone
- 0Department of Social and Political Sciences, Bocconi University, Milan, Italy
- Erika Stucchi
- 1Medical Oncology and Hematology Unit, IRCCS Humanitas Research Hospital, Milan, Italy
- Erika Stucchi
- 2Department of Biomedical Sciences, Humanitas University, Milan, Italy
- Luigi Lorini
- 1Medical Oncology and Hematology Unit, IRCCS Humanitas Research Hospital, Milan, Italy
- Cristina Gurizzan
- 1Medical Oncology and Hematology Unit, IRCCS Humanitas Research Hospital, Milan, Italy
- Ksenia Khelik
- 3Centre for Bioinformatics, Department of Informatics, University of Oslo, Oslo, Norway
- Eivind Hovig
- 3Centre for Bioinformatics, Department of Informatics, University of Oslo, Oslo, Norway
- Eivind Hovig
- 4Department of Tumor Biology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway
- Andreas Dietz
- Clinic of Otolaryngology, Head and Neck Surgery, Department of Head Medicine and Oral Health, University Hospital Leipzig, Leipzig, Germany
- Cesare Piazza
- Unit of Otorhinolaryngology – Head and Neck Surgery, ASST Spedali Civili di Brescia, Brescia, Italy
- Cesare Piazza
- Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia, Brescia, Italy
- Paolo Bossi
- 1Medical Oncology and Hematology Unit, IRCCS Humanitas Research Hospital, Milan, Italy
- Paolo Bossi
- 2Department of Biomedical Sciences, Humanitas University, Milan, Italy
- DOI
- https://doi.org/10.3389/fonc.2024.1433333
- Journal volume & issue
-
Vol. 14
Abstract
In locally advanced (LA) laryngeal/hypopharyngeal squamous cell carcinoma (LHSCC), larynx preservation (LP) strategies aim at the cure of the disease while preserving a functional larynx, thus avoiding total laryngectomy and the associated impact on the quality of life. In the last decades, apart from transoral and open-neck organ preservation approaches, several non-surgical regimens have been investigated: radiotherapy alone, alternate, concurrent or sequential chemoradiation, and bioradiotherapy. Despite major progress, the identification of reliable and effective predictors for treatment response remains a clinical challenge. This review examines the current state of LP in LA-LHSCC and the need for predictive factors, highlighting the importance of the PRESERVE trial in addressing this gap. The PRESERVE trial represents a pivotal initiative aimed at finding the optimal therapy for laryngeal preservation specific to each patient through a retrospective analysis of data from previous LP trials and prospectively validating findings. The goal of the PRESERVE trial is to develop a comprehensive predictive classifier that integrates clinical, molecular, and multi-omics data, thereby enhancing the precision and efficacy of patient selection for LP protocols.
Keywords
